← Back to headlines
Ultragenyx Pharmaceutical Gains Bullish Sentiment Ahead of Angelman Trial
Ultragenyx Pharmaceutical is garnering bullish sentiment from investors in anticipation of its forthcoming GTX-102 Phase 3 trial for Angelman Syndrome, signaling confidence in its clinical development.
29 Apr, 13:17 — 29 Apr, 13:17
Sources
Showing 1 of 1 sources
